Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Healthcare investment company Syncona reported a 7.2% loss for the six months to the end of September as its portfolio was weighted down by a fall in the share price of one of its holdings.
Autolus, a NASDAQ-listed therapeutics company, declined by 61% during the period, outweighing significant returns that Syncona banked from the sale of Blue Earth Diagnostics and Nightstar, as well as a Series B financing in Achilles Therapeutics. Syncona said it continued to believe in Autolus' strong fundamentals.
Net assets at 30 September 2019 totalled £1,336.8m, down from £1,455.1m at the end of March.
Syncona's capital base increased by £455.8m to £855.5m during the period, and it expects to deploy £200-250m for the full financial year.